Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. - Wikidata - wikimedia - TriplyDB

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

http://www.wikidata.org/entity/Q38409647

about

Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus.Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes.Insulin analogues in type 1 diabetes mellitus: getting better all the time.Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use.Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes.Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Between Insulin Degludec and Insulin Glargine (100 U/mL and 300 U/mL): A Comparison Across Studies.Insulin degludec overdose may lead to long-lasting hypoglycaemia through its markedly prolonged half-life.Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study.Quality-of-life and treatment satisfaction in actual clinical practice of patients with Type 1 diabetes mellitus (T1DM) and hypoglycemia treated with insulin degludec.Comparison of insulin degludec with insulin detemir in type 1 diabetes: a 1-year treat-to-target trial.The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.Advances in Basal Insulin Therapy.

P2860

Q33835638-6D542871-00E7-4583-B2D1-4D1CE04D4160 Q36637960-4026504C-A24E-4926-A7ED-234906BEE313 Q37060869-2ADA8D25-6E75-47AC-A8E4-4CDF019C69FD Q37561045-91C35C50-9B8C-4545-9B54-632CD336E712 Q38604382-A88385C7-5BEF-45B9-83F1-D81407716E0A Q38672852-18EE1CA0-05DC-4948-AD89-BDE71741C3AE Q38689189-AF4FF40C-0E44-4516-9DC4-83EA886AE122 Q38692387-97CF6289-1A3E-4A58-8FC0-A09DC670B212 Q38824504-F8374BFD-CBB1-4985-9998-D7D36410BAE5 Q38970550-15671F0A-B227-4F5E-890B-4C1E346E3658 Q39115000-CC868051-7592-495F-B6D7-53FCCA631A70 Q42383447-BA3E2757-310C-4A7F-ABBB-8BCD70B02026 Q44512290-673ABCFF-EA98-4482-A411-E1F6C8CBFC1B Q47925155-22AEDDCF-9FC4-412B-8263-18619D6BFE27 Q48232532-88D8BA7C-A610-4256-B01D-BBAC5C73EDA9 Q48262568-01708BC9-C73D-4B57-893E-1B38C06773CE Q50195979-58921EF4-DAAA-40C6-8241-77B78277C032 Q51296086-6D2752F9-4595-4BAC-AFBB-CC42FB24B316 Q53449720-8E39F646-C13D-4915-9D8D-F7037D496105 Q55309585-EC997509-F0B1-4BC3-AA9E-B9F3C965CBAF

P2860

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.

http://www.wikidata.org/entity/Q38409647

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Comparison of the pharmacokine ...... degludec and insulin glargine.

@en

type

label

Comparison of the pharmacokine ...... degludec and insulin glargine.

@en

prefLabel

Comparison of the pharmacokine ...... degludec and insulin glargine.

@en

P1433

Q38409647-D8704D9E-B217-4C01-A023-A7FA0F3FF1C0

P1476

Q38409647-91EA0BDE-C857-4B87-B0F6-BA62980F1A6F

P2093

Q38409647-00F3DD55-B8A4-4D89-8991-509A105A28C0

Q38409647-0E8CFDB4-C6FD-40AF-8407-110DF275EABB

Q38409647-107C24B9-E873-4B23-B5DE-30CC1ED0C9A5

Q38409647-91B2207A-807E-4132-B420-5803D1AED609

Q38409647-9897BD9C-FF53-43CC-B2C2-441761A637AC

Q38409647-C2B7598C-00C9-430B-9430-0F0595FDEFF8

P2860

Q38409647-4165C5A0-5288-4139-B025-250FAB472EA6

Q38409647-50B312F8-B9E1-4F62-AFEF-6B7BB2F5EB47

Q38409647-5A8C20E0-8C0A-4A23-86DB-EE7D99BA90BA

Q38409647-72038CEC-4973-4798-B331-A11D86ABEB5B

Q38409647-8D734743-5DE8-4B72-BE5B-F96B274C3BDE

Q38409647-940A07D0-A95E-4257-8D56-89206A812B89

Q38409647-95CFFCB2-6EC2-48FC-80E7-2A94D262C7B2

Q38409647-96AFC30C-B1A6-4F2B-83D8-91AF70146F52

Q38409647-9EB32AE8-5262-4C76-A386-EFC9EA20016E

Q38409647-AF5D7928-0ED7-437D-B6D6-26C1A30C94EE

P304

Q38409647-20B8BA06-3975-44F6-9361-CE195E68E903

P31

Q38409647-2CC137F4-225C-4F76-9D33-BED8DA3A294F

P356

Q38409647-590C73CB-6DA5-45BF-A047-1D4A9A62AA3D

P407

Q38409647-E0317DB9-0E02-40C3-9529-9AC3DF1522E8

P433

Q38409647-E99DB529-D79A-4378-A985-DC64C6F7A925

P478

Q38409647-DFAAEA77-4C1E-49BA-AEAA-43256A95FBE0

P577

Q38409647-7B267723-D0DA-4917-8D77-AFF32D5A4654

P698

Q38409647-B745DD50-DCB7-481B-94D4-3BA31725D5B7

P356

17425255.2015.1058779

P1433

Expert Opinion on Drug Metabolism & Toxicology

P1476

Comparison of the pharmacokine ...... degludec and insulin glargine.

@en

P2093

Hanne Haahr

http://www.w3.org/2001/XMLSchema#string

Leszek Nosek

http://www.w3.org/2001/XMLSchema#string

Lidia Hermanski

http://www.w3.org/2001/XMLSchema#string

Susanne G Bøttcher

http://www.w3.org/2001/XMLSchema#string

Tim Heise

http://www.w3.org/2001/XMLSchema#string

Ulrike Hövelmann

http://www.w3.org/2001/XMLSchema#string

P2860

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application.

Insulin stacking versus therapeutic accumulation: understanding the differences.

P304

1193-1201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.1058779

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26086190

http://www.w3.org/2001/XMLSchema#string